For the first time in 18 years, a new drug for Alzheimer’s disease hit the market this week.
It’s the best example I’ve ever seen of precision medicine at work.
For me, this isn’t just a fantastic health care advancement — it’s personal. I lost my father to Alzheimer’s seven years ago, when drugs like this one did not exist.
And, as an investor, I’m also thrilled at the drug’s approval because it is proof that precision medicine is going mainstream.
That underscores the phenomenal profit potential for biotech investors who tap this major America 2.0 medical trend.
In fact, I’d call it taking medicine to the “next level.”
And because of that, I’m going to tell you how you can bring your portfolio along for the ride up.
30% Is Not Enough for Effective Alzheimer’s Treatments
After a long string of Big Pharma failures, Alzheimer’s researchers are finally making progress on new treatments, such as the newly approved drug called aducanumab.
The big kicker with this drug is that it uses precision medicine.
Unlike the blanket medicine approach — one treatment for every person — it targets an underlying, genetically linked cause of the disease.
The America 2.0 next-level breed of Alzheimer’s drugs actually eliminates the buildup of toxic proteins in the brain that cause memory loss and confusion.
That’s huge because, according to a study from the Personalized Medicine Coalition, 70% of Alzheimer’s drugs on average are NOT effective.
Even for those folks who do benefit from the old-world drugs, they merely ease symptoms.
So, this newly approved drug — and others in the pipeline just like it — are like precise chemical ninja warriors that fight specific genetic and biological traits that cause Alzheimer’s.
That makes them safer, better and more effective.
They don’t work for every dementia patient. But that’s precisely the point. They are not “one size fits all” meds. They are tailor-made therapies designed to help those with the specific genetic and biological traits they target.
Through gene tests and PET scans of the brain, doctors can identify those at risk for Alzheimer’s to treat with these drugs years or even decades before memory loss develops.
But here’s the big picture: This targeted approach is not only a breakthrough for Alzheimer’s disease.
I believe it opens the door to other precision medicine drugs that target underlying biological and genetic factors that lead to virtually every other health condition.
These new-world precision medicine drugs could soon be as common as old-world cholesterol-lowering statins that tens of millions take to combat heart disease.
Now, just imagine you had the chance to invest in the first companies that developed statins. The statins market is set to hit billions.
The precision medicine market? Even bigger… It’s expected to rise to $216.75 billion by 2028.
That tells me the time to invest is now. It’s time to take your portfolio to the next level as our health care steps it up for America 2.0.
10 Precision Medicine Stocks in 1 Portfolio
Our outdated health care system is quickly stepping into America 2.0 through precision medicine.
This next wave is not only good for us medically … it could be great for our investments.
In fact, I recently sat down with Paul to hear about his new take on “next-level” investing. And talk about fortunes favoring the bold!
This is the secret behind his best stock returns over the last five years.
Stocks leading the way on America 2.0 mega trends, such as precision medicine, that are changing our world.
I took a look this morning and he has 10 incredible precision medicine recommendations in the open next-level model portfolio.
You can see our full interview here:
But take the time to check it out today. You see, this video is jampacked with his exclusive trading details for this strategy.
And we can’t leave it out there for the world to see … or Paul’s readers would lose their advantage.
So — in hours — it’s coming offline.
Trust me, if you’re as blown away as I was, you won’t regret taking the time to watch.
To your health and wealth,
Senior Editorial Manager, Banyan Hill Publishing